AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20491724 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonnic nicotine lozenge (2.5 mg)
Number of subjects: 47
Study 20491724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorette gum (4 mg)
Number of subjects: 47
Study 20491724 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 47
Study 17493526 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept group
Number of subjects: 28
Study 17493526 — intervention group
Group type: COMPARATOR
Intervention: CsA group
Number of subjects: 28
Study 15716708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 7665
Study 12537316 — intervention group
Group type: EXPERIMENTAL
Intervention: New partially hydrolyzed formula
Number of subjects: 16
Study 12537316 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula
Number of subjects: 16
Study 10354839 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized low-weight polypropylene mesh (26.8 g/m2, pore size 5 mm)
Number of subjects: 0
Study 10354839 — intervention group
Group type: COMPARATOR
Intervention: Common heavy-weight polypropylene mesh (90.2 g/m2, pore size 0.8 mm)
Number of subjects: 0
Study 7493424 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ouabain
Number of subjects: 20
Study 7493424 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral digoxin
Number of subjects: 20
Study 7493424 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amiloride
Number of subjects: 20
Study 7493424 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control)
Number of subjects: 20
Study 7493424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients
Number of subjects: 20
Study 30915963 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch-observation and task-based mirror therapy
Number of subjects: 12
Study 30915963 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 28859943 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for abdominal aortic aneurysm, peripheral arterial disease, and hypertension
Number of subjects: 50156
Study 28859943 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 50156
Study 26547411 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 250
Study 26547411 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 250
Study 26547411 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin and Vancomycin
Number of subjects: 250
Study 24053702 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy
Number of subjects: 0
Study 24053702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 0
Study 21223512 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg twice daily)
Number of subjects: 87
Study 21223512 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1 g twice daily)
Number of subjects: 87
Study 21223512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 18318133 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiferon (recombinant alpha2beta‐interferon)
Number of subjects: 0
Study 18318133 — intervention group
Group type: COMPARATOR
Intervention: Arbidol
Number of subjects: 0
Study 15983318 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (0.4 mg cerivastatin daily, later replaced by 20 mg simvastatin)
Number of subjects: 250
Study 15983318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 12802487 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 117
Study 12802487 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 117
Study 10937115 — intervention group
Group type: EXPERIMENTAL
Intervention: 35-mm camera (Nikon 6006)
Number of subjects: 13
Study 10937115 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympus D600L digital camera
Number of subjects: 13
Study 10937115 — intervention group
Group type: EXPERIMENTAL
Intervention: Kodak DCS 315 digital camera
Number of subjects: 13
Study 10937115 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympus D320L digital camera
Number of subjects: 13
Study 8649569 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 600 mg/day
Number of subjects: 190
Study 8649569 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 800 mg/day
Number of subjects: 190
Study 8649569 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 1,000 mg/day
Number of subjects: 190
Study 8649569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 1900685 — intervention group
Group type: COMPARATOR
Intervention: UFT
Number of subjects: 210
Study 1900685 — intervention group
Group type: EXPERIMENTAL
Intervention: tegafur
Number of subjects: 210
Study 6509109 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (MU)
Number of subjects: 20
Study 6509109 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training phrases and music (ATP & MU)
Number of subjects: 20
Study 6509109 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 30080428 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual tDCS (20 min of anodal stimulation of the motor cortex at 2 mA)
Number of subjects: 8
Study 30080428 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 8
Study 30409103 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual group (gradual changes in treadmill belts speed during adaptation)
Number of subjects: 26
Study 30409103 — intervention group
Group type: COMPARATOR
Intervention: Abrupt group (a single, large, abrupt change during adaptation)
Number of subjects: 26
Study 26269397 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg/week
Number of subjects: 208
Study 26269397 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 208
Study 25261913 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed total shoulder prosthesis (Delta X-tend)
Number of subjects: 120
Study 25261913 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation with angular stable plate (Philos) and thread cerclage
Number of subjects: 120
Study 22223097 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose drink
Number of subjects: 18
Study 22223097 — intervention group
Group type: EXPERIMENTAL
Intervention: fat drink
Number of subjects: 18
Study 22223097 — intervention group
Group type: EXPERIMENTAL
Intervention: protein drink
Number of subjects: 18
Study 22223097 — intervention group
Group type: COMPARATOR
Intervention: placebo drink
Number of subjects: 18
Study 21176197 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment of malaria in infants (IPTi)
Number of subjects: 0
Study 19052352 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Magnesium Sulphate (2g)
Number of subjects: 60
Study 19052352 — intervention group
Group type: COMPARATOR
Intervention: Control (IV normal saline)
Number of subjects: 60
Study 15650664 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone (BPTB) graft
Number of subjects: 134
Study 15650664 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-strand semitendinosus (ST) graft
Number of subjects: 134
Study 15650664 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-strand semitendinosus/gracilis (ST/G) graft
Number of subjects: 134
Study 15650664 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (BPTB, ST, ST/G)
Number of subjects: 134
Study 12460326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 10 mg
Number of subjects: 50
Study 12460326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 20 mg
Number of subjects: 50
Study 12460326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg
Number of subjects: 50
Study 12460326 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg
Number of subjects: 50
Study 12460326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12198789 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-D structure
Number of subjects: 0
Study 12198789 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-D structure
Number of subjects: 0
Study 12198789 — intervention group
Group type: EXPERIMENTAL
Intervention: ALCOVE model
Number of subjects: 0
Study 12198789 — intervention group
Group type: COMPARATOR
Intervention: Rational model
Number of subjects: 0
Study 12198789 — intervention group
Group type: COMPARATOR
Intervention: Configural-cue model
Number of subjects: 0
Study 7501203 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care styles
Number of subjects: 69
Study 2029326 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with husbands' lymphocytes
Number of subjects: 99
Study 2029326 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with third party lymphocytes
Number of subjects: 99
Study 2029326 — intervention group
Group type: COMPARATOR
Intervention: Control group (immunized with their own lymphocytes)
Number of subjects: 99
Study 7014814 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid rate ventilation (20 to 40/minute with a one-second inspiratory time)
Number of subjects: 0
Study 7014814 — intervention group
Group type: COMPARATOR
Intervention: Slow rate ventilation (60/minute with 0.5 second inspiratory time)
Number of subjects: 0
Study 7014814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 30689825 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 0
Study 30689825 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 0
Study 29766257 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week walking-based exercise intervention consisting of 28 walking sessions, with 1 session per week supervised by a trained physiotherapist, spread over a maximum of 8 weeks (2-5 times/week)
Number of subjects: 0
Study 29766257 — intervention group
Group type: COMPARATOR
Intervention: Exercise advice on the benefits of exercise for people with RA
Number of subjects: 0
Study 27021781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tested with multiple-choice knowledge questions and provided feedback after each 5-min segment
Number of subjects: 120
Study 27021781 — intervention group
Group type: COMPARATOR
Intervention: Tested with multiple-choice knowledge questions but not provided feedback
Number of subjects: 120
Study 27021781 — intervention group
Group type: COMPARATOR
Intervention: Watched the video without knowledge testing
Number of subjects: 120
Study 24176997 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 110/50 μg
Number of subjects: 247
Study 24176997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 24176997 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg
Number of subjects: 247
Study 22490579 — intervention group
Group type: EXPERIMENTAL
Intervention: rhNRG‐1 (10 μg·kg‐1·d‐1, I.V.) for 10 days
Number of subjects: 29
Study 22490579 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 29
Study 22490579 — intervention group
Group type: COMPARATOR
Intervention: Sham-operated animals (no treatment)
Number of subjects: 29
Study 20649629 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (evening regimen)
Number of subjects: 3181
Study 20649629 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (morning regimen)
Number of subjects: 3181
Study 18616492 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of melatonin 60 min before the procedure (group I)
Number of subjects: 60
Study 18616492 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg(‐1) melatonin 60 min before the procedure (group II)
Number of subjects: 60
Study 18616492 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg.kg(‐1) midazolam 15 min before the procedure (group III)
Number of subjects: 60
Study 18616492 — intervention group
Group type: COMPARATOR
Intervention: 3 ml of 0.09 NaCl 15 min (group IV)
Number of subjects: 60
Study 18616492 — intervention group
Group type: COMPARATOR
Intervention: 3 ml of 0.09 NaCl 60 min (group IV)
Number of subjects: 60
Study 16554449 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (10 mg, 25 mg, 50 mg)
Number of subjects: 62
Study 16554449 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 62
Study 14583186 — intervention group
Group type: COMPARATOR
Intervention: CCR5-del32 allele in type I diabetes patients
Number of subjects: 149
Study 14583186 — intervention group
Group type: COMPARATOR
Intervention: CCR5-del32 allele in type II diabetes patients
Number of subjects: 149
Study 14583186 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type CCR5 genotype in type I diabetes
Number of subjects: 149
Study 14583186 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type CCR5 genotype in type II diabetes
Number of subjects: 149
Study 10553829 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg rapacuronium
Number of subjects: 75
Study 10553829 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rapacuronium
Number of subjects: 75
Study 10553829 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg rapacuronium
Number of subjects: 75
Study 8723577 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 50 to 150 IU/kg SC plus i.v. iron twice weekly for 3 weeks
Number of subjects: 0
Study 8723577 — intervention group
Group type: COMPARATOR
Intervention: i.v. iron alone
Number of subjects: 0
Study 8723577 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study 1929509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 0.625 mg/kg
Number of subjects: 93
Study 1929509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1.25 mg/kg
Number of subjects: 93
Study 1929509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 2.5 mg/kg
Number of subjects: 93
Study 1929509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 5 mg/kg
Number of subjects: 93
Study 6135300 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (400 micrograms, 1 ml injection)
Number of subjects: 30
Study 6135300 — intervention group
Group type: COMPARATOR
Intervention: Sodium Chloride (0.9%, 1 ml injection)
Number of subjects: 30
Study 30672091 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (IgPro10, Privigen)
Number of subjects: 235
Study 29159694 — intervention group
Group type: EXPERIMENTAL
Intervention: SDPM-CIP tablets
Number of subjects: 0
Study 29159694 — intervention group
Group type: COMPARATOR
Intervention: CIPRO XR® bilayer tablets
Number of subjects: 0
Study 28207527 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhibitai 480 mg + atorvastatin 10 mg (ZA10 group)
Number of subjects: 150
Study 28207527 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg (A40 group)
Number of subjects: 150
Study 28207527 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg (A20 group)
Number of subjects: 150
Study 26180243 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g α-GOSs/d
Number of subjects: 88
Study 26180243 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g α-GOSs/d
Number of subjects: 88
Study 26180243 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 g α-GOSs/d
Number of subjects: 88
Study 26180243 — intervention group
Group type: COMPARATOR
Intervention: Control (glucose syrup)
Number of subjects: 88
Study 23979955 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (6 years total exposure)
Number of subjects: 4550
Study 23979955 — intervention group
Group type: COMPARATOR
Intervention: Denosumab (3 years crossover from placebo)
Number of subjects: 4550
Study 21371498 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (360 min/week of moderate-to-vigorous aerobic exercise)
Number of subjects: 202
Study 21371498 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 202
Study 18322873 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 21
Study 18322873 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment (endoluminal stenting)
Number of subjects: 21
Study 17725149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (0.5 gram per capsule, 2 capsules taken one hour before surgery)
Number of subjects: 120
Study 17725149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12716661 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans meal (10% energy from trans 18:1 acids)
Number of subjects: 19
Study 12716661 — intervention group
Group type: COMPARATOR
Intervention: Cis meal (10% energy from oleic acid)
Number of subjects: 19
Study 12716661 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans meal
Number of subjects: 19
Study 12716661 — intervention group
Group type: COMPARATOR
Intervention: Cis meal
Number of subjects: 19
Study 10739506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 17beta-estradiol (300 microg/d)
Number of subjects: 659
Study 10739506 — intervention group
Group type: COMPARATOR
Intervention: Oral micronized estradiol (2 mg/d)
Number of subjects: 659
Study 9189968 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine 0.4% eyedrops
Number of subjects: 40
Study 9189968 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 0.1% eyedrops
Number of subjects: 40
Study 8409683 — intervention group
Group type: EXPERIMENTAL
Intervention: razoxane
Number of subjects: 603
Study 2985351 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 10
Study 2985351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30102886 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue massage (20-minute session)
Number of subjects: 165
Study 30102886 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 165
Study 30102886 — intervention group
Group type: COMPARATOR
Intervention: Individualized attention (20 minutes)
Number of subjects: 165
Study 27229315 — intervention group
Group type: EXPERIMENTAL
Intervention: KMC with a woolen cap
Number of subjects: 0
Study 27229315 — intervention group
Group type: COMPARATOR
Intervention: KMC without a woolen cap
Number of subjects: 0
Study 26051802 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 Gy plus 90 Gy (103)Pd
Number of subjects: 0
Study 26051802 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy with 115 Gy (103)Pd
Number of subjects: 0
Study 26051802 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy (20/0 trial)
Number of subjects: 0
Study 26051802 — intervention group
Group type: COMPARATOR
Intervention: 0 Gy (20/0 trial)
Number of subjects: 0
Study 23181832 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg folic acid
Number of subjects: 6000
Study 23181832 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg folic acid
Number of subjects: 6000
Study 23181832 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 6000
Study 20970382 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-neurturin (5·4 × 10¹¹ vector genomes) injected bilaterally into the putamen
Number of subjects: 58
Study 20970382 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 58
Study 19192860 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) program with gift certificates for compliance delivered at 4- to 6-week intervals, total value = $390.00, with escalating gift certificates by $5.00 increments.
Number of subjects: 0
Study 19192860 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) program with higher magnitude gift certificates and gradually decreased density of reinforcement.
Number of subjects: 0
Study 15794392 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Injection Anxiety Therapy (SIAT)
Number of subjects: 30
Study 15794392 — intervention group
Group type: COMPARATOR
Intervention: Control telephone support condition
Number of subjects: 30
Study 12213353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin
Number of subjects: 33
Study 12213353 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 33
Study 12213353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 10036345 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 1 mg (4 puffs) plus 2.5 mg nebulized salbutamol
Number of subjects: 54
Study 10036345 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 2.5 mg nebulized salbutamol
Number of subjects: 54
Study 10036345 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 54
Study 10036345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 7793584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac
Number of subjects: 60
Study 7793584 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine
Number of subjects: 60
Study 1778084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ser-316 suppository (3 suppositories/week for 6 months)
Number of subjects: 47
Study 1778084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 371339 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomepromazine, 12.5 mg
Number of subjects: 316
Study 371339 — intervention group
Group type: COMPARATOR
Intervention: Pethidine, 50 mg
Number of subjects: 316
Study 371339 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomepromazine
Number of subjects: 316
Study 371339 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 316
Study 371339 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomepromazine and Pethidine
Number of subjects: 316
Study 31679359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish + Walnut diet (150 g fish and 9 walnuts/week)
Number of subjects: 99
Study 31679359 — intervention group
Group type: COMPARATOR
Intervention: Fish diet (300 g/week)
Number of subjects: 99
Study 31679359 — intervention group
Group type: COMPARATOR
Intervention: Walnut diet (18 walnuts/week)
Number of subjects: 99
Study 27913695 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ 2,400 mg/d
Number of subjects: 609
Study 27913695 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 609